Drugs / IBI397
last change Aug 2023 re-read 2 minutes ago

IBI397

Developed for
cancer
Investigated by
Innovent Biologics (Suzhou) Co. Ltd.

Trials 1 · a red edge is where a trial was stopped

2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05245916 Apr 2022 → Aug 2023 cancer Innovent Biologics (Suzhou) Co. Ltd. Withdrawn No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as IBI397 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05245916